
<!DOCTYPE html>
<html lang="en-US" class=" js">
<head>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-1CD9F90731"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-1CD9F90731');
</script>


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-8495225890363177"
     crossorigin="anonymous"></script>
     
 

<link rel="stylesheet" href="https://education-academia.github.io/css/bootstrap.min.css">
<link rel="stylesheet" href="https://education-academia.github.io/css/style.css">
<link rel="stylesheet" href="https://education-academia.github.io/css/custom.css">
<link rel="icon" href="https://education-academia.github.io/images/favicon.png" type="image/x-icon">
<link href="https://cdn.rawgit.com/westonganger/bootstrap-directional-buttons/master/dist/bootstrap-directional-buttons.css" rel="stylesheet" type="text/css">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Name the Associate professor of University of Texas at San Antonio, who has developed a newly patented method to kill cancer cells recently
</title>
<meta name="description" content="NACOGDOCHES, Texas-Dr. Matibur Zamadar, Stephen F. Austin State University associate professor in the Department of Chemistry and Biochemistry, has received a patent from the U.S. Patent and Trademark Office for his invention regarding therapeutic treatment of bacteria and cancers, and fluorescence diagnosis.The compound, designated EBC-46 and technically called tigilanol tiglate, works by promoting a localized immune response against tumors. The response breaks apart the tumors blood vessels and ultimately kills its cancerous cells.Dr. Jung-Mo Ahn, associate professor of chemistry and biochemistry at UT Dallas, synthesized a novel compound called ERX-41 that has shown promise in eliminating cancer cells.The FDA-approved drug, called Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is a new radiation pharmaceutical that is administered through injection or infusion.On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).">
<meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1'>
<meta name="keywords" content=" What is the newly discovered cancer drug?, Which scientist discovered a new molecule that kills even the deadliest cancer?, What is the newest treatment for prostate cancer?, What is the new cancer medicine for 2022?, What new colon cancer drug was approved by the FDA 2022?, What are the top 3 most common new case cancer types 2022?, What is the most common surgical treatment for cancer of the prostate?, Which is the best prostate cancer treatment in India?, What is the new advanced prostate cancer drug available in Canada? ">
</head>
<body data-rsssl="1" class="page-template-default custom-background custom-background-white custom-font-enabled single-author" style="padding: 0px 0px 154px;">
<div id="page" class="site" style="height: auto !important;">
<header id="masthead" class="site-header" role="banner">
<div class="io-title-description">
<a href="https://education-academia.github.io" title="Change your future" rel="home">EDUCATION FOR ALL
</a>
<br>
<a class="site-description">The MCQ hub
</a>
</div>
<nav id="site-navigation" class="themonic-nav" role="navigation">
<a class="assistive-text" href="#main" title="Skip to content">Skip to content
</a>
<ul id="menu-top" class="nav-menu">
<li id="menu-item-695195" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-695195">
<a href="https://education-academia.github.io/">Home
</a>
</li>
</ul>
<select class="selectnav" id="selectnav1">
<option value="">Menu
</option>
<option value="https://education-academia.github.io">HOME
</option>
</select>
</nav>
<!-- #site-navigation -->
<div class="clear">
</div>
</header>
<!-- #masthead -->
<div id="main" class="wrapper">
<div id="primary" class="site-content">
<div id="content" role="main">
<article id="post-1014223" class="post-1014223 page type-page status-publish hentry">
<header class="entry-header">
<h1 class="entry-title"> CURRENT AFFAIRS
</h1>
</header>
<div class="entry-content">
<div class="f-l">
<a href="https://education-academia.github.io/current-affairs/2016/recently-the-government-will-invest-how-much-for-northeast-region-to-develop-road-infrastructure-in-five-years-by-the-union-road-transport-and-highways-ministry.html" class="btn btn-info btn-arrow-left" role="button" aria-pressed="true">Previous
</a>
</div>
<div class="f-r">
<a href="https://education-academia.github.io/current-affairs/2016/the-24th-national-childrens-science-congress-ncsc-was-held-in-which-city.html" class="btn btn-info btn-arrow-right" role="button" aria-pressed="true">Next
</a>
</div>
<div style="text-align:center">
<h2>2016 
</h2>
<h3>
</h3>
<p style="text-align: center;">
<a href="https://drive.google.com/drive/folders/1JxfIMvv4AW-4Jl_pC6NHChgZJETuMZiE?usp=share_link" target="_blank" rel="noopener">
<span style="color: #008000;">
<strong>DOWNLOAD FREE PDF BOOK (USEFUL FOR TEACHERS/INSTRUCTORS/COACHING INSTITUTES)
</strong>
</span>
<span style="color: #ff0000;">
<img src="https://education-academia.github.io/download.gif">
</span>
</a>
</p>
</div>
<strong> Name the Associate professor of University of Texas at San Antonio, who has developed a newly patented method to kill cancer cells recently 
</strong>
<p>(A) Thomas G. Forsthuber 
</p>
<p>(B) Mark Eppinger 
</p>
<p>(C) Luis S. Haro 
</p>
<p>(D) ** Matthew Gdovin 
</p>
<p>
<div style ="text-align:center">
<h3>EXPLANATIONS BELOW
</h3>
</div>
<p>
<strong>Concept note-1:
</strong>-NACOGDOCHES, Texas-Dr. Matibur Zamadar, Stephen F. Austin State University associate professor in the Department of Chemistry and Biochemistry, has received a patent from the U.S. Patent and Trademark Office for his invention regarding therapeutic treatment of bacteria and cancers, and fluorescence diagnosis.
</p>
<p>
<strong>Concept note-2:
</strong>-The compound, designated EBC-46 and technically called tigilanol tiglate, works by promoting a localized immune response against tumors. The response breaks apart the tumorâ€™s blood vessels and ultimately kills its cancerous cells.
</p>
<p>
<strong>Concept note-3:
</strong>-Dr. Jung-Mo Ahn, associate professor of chemistry and biochemistry at UT Dallas, synthesized a novel compound called ERX-41 that has shown promise in eliminating cancer cells.
</p>
<p>
<strong>Concept note-4:
</strong>-The FDA-approved drug, called Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is a new radiation pharmaceutical that is administered through injection or infusion.
</p>
<p>
<strong>Concept note-5:
</strong>-On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). 
<div class="f-l">
<a href="https://education-academia.github.io/current-affairs/2016/recently-the-government-will-invest-how-much-for-northeast-region-to-develop-road-infrastructure-in-five-years-by-the-union-road-transport-and-highways-ministry.html" class="btn btn-info btn-arrow-left" role="button" aria-pressed="true">Previous
</a>
</div>
<div class="f-r">
<a href="https://education-academia.github.io/current-affairs/2016/the-24th-national-childrens-science-congress-ncsc-was-held-in-which-city.html" class="btn btn-info btn-arrow-right" role="button" aria-pressed="true">Next
</a>
</div>
<p style="text-align: center;">
<a href="https://play.google.com/store/books/author?id=Narayan+Changder" target="_blank" rel="noopener">
<span style="color: #008000;">
<strong>BUY E-BOOK WITH ANSWER KEYS GIVEN AT THE END OF EVERY PAGE
</strong>
</span>
<span style="color: #ff0000;">
<img src="https://education-academia.github.io/buynow.webp">
</span>
</a>
</p>
</div>
<!-- .entry-content -->
<footer class="entry-meta">
</footer>
<!-- .entry-meta -->
</article>
<!-- #post -->
<div id="comments" class="comments-area">
</div>
<!-- #comments .comments-area -->
</div>
<!-- #content -->
</div>
<!-- #primary -->
<div id="secondary" class="widget-area" role="complementary">
<aside id="search-3" class="widget widget_search">
<ul>
<li>
<a href="https://education-academia.github.io/current-affairs/2016/1.html">
<strong>CURRENT AFFAIRS-2016
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2017/1.html">
<strong>CURRENT AFFAIRS-2017 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2018/1.html">
<strong>CURRENT AFFAIRS-2018 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2019/1.html">
<strong>CURRENT AFFAIRS-2019 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2020/1.html">
<strong>CURRENT AFFAIRS-2020 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2021/1.html">
<strong>CURRENT AFFAIRS-2021 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2022/1.html">
<strong>CURRENT AFFAIRS-2022 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2023/1.html">
<strong>CURRENT AFFAIRS-2023 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2024/1.html">
<strong>CURRENT AFFAIRS-2024 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2025/1.html">
<strong>CURRENT AFFAIRS-2025
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2026/1.html">
<strong>CURRENT AFFAIRS-2026
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2027/1.html">
<strong>CURRENT AFFAIRS-2027
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2028/1.html">
<strong>CURRENT AFFAIRS-2028 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2029/1.html">
<strong>CURRENT AFFAIRS-2029 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/2030/1.html">
<strong>CURRENT AFFAIRS-2030 
</strong>
</a>
</li>
<li>
<a href="https://education-academia.github.io/current-affairs/miscellaneous/1.html">
<strong>CURRENT AFFAIRS-MISCELLANEOUS 
</strong>
</a>
</li>
</ul>
</aside>
</div>
<!-- #secondary -->
</div>
<!-- #main .wrapper -->
<footer id="colophon" role="contentinfo">
<div class="site-info">
<div class="footercopy">
</div>
<div class="footercredit">
</div>
<div class="clear">
</div>
</div>
<!-- .site-info -->
</footer>
<!-- #colophon -->
<div class="site-wordpress">
</div>
<!-- .site-info -->
<div class="clear">
</div>
</div>
<!-- #page -->
<script src="https://education-academia.github.io/js/jquery.min.js">
</script>
<script src="https://education-academia.github.io/js/bootstrap.min.js">
</script>
</body>
</html>